On Monday, BofA Securities revised its stance on shares of Fresenius Medical Care (NYSE:FMS), moving the rating from Underperform to Neutral and increasing the price target to $24.00, up from the previous $18.00.
The adjustment follows the observation that Fresenius Medical (TASE:PMCN) Care's essential performance indicators, such as treatment volume, margin expansion relative to its 2025 objectives, and leverage, have begun to show signs of improvement.
Currently trading at $22.02 with a market capitalization of $13.2 billion, InvestingPro analysis suggests the stock is undervalued, with a "GOOD" overall financial health score.
The analyst from BofA Securities noted that the company's setup for 2025 now appears more favorable than it did a year ago, despite sell-side expectations remaining relatively modest.
The projection for EBIT margin is now at 10.8%, slightly above the consensus of 10.7%, and within the company's guided range of 10-14%. Both the Clinical and Commercial divisions are expected to meet their target ranges, aided by ongoing savings from management efforts.
With an EPS forecast of $3.01 for FY2024 and a P/E ratio of 19x, the company shows promising growth potential. InvestingPro subscribers can access 10+ additional key metrics and insights about FMS's valuation.
The raised earnings per share (EPS) estimates for 2024-25, which have increased by 4-9%, reflect a growing confidence in Fresenius Medical Care's ability to achieve its 2025 targets. The analyst pointed out that the stock has already seen a year-to-date performance increase of 11%, in contrast to the MSCI Health Care Europe index, which has declined by 2.5%.
Despite the upgrade and raised price target, the BofA Securities analyst expressed continued caution regarding the dialysis market, which is perceived as structurally challenged due to potential long-term risks such as SGLTs/GLP-1s and the possibility of reimbursement changes, notably from ACA exchanges.
The new price objective of €45 per American Depositary Receipt (ADR), equivalent to $24, reflects these considerations and the improved fundamentals of Fresenius Medical Care. Notably, the company has maintained dividend payments for 27 consecutive years, demonstrating strong financial stability.
For a comprehensive analysis of FMS's market position and future prospects, investors can access the detailed Pro Research Report available on InvestingPro.
In other recent news, Fresenius Medical Care, a prominent dialysis services provider, showcased resilience and growth in its Third Quarter 2024 Earnings Call despite significant challenges. The company reported a 2% organic revenue growth and a 10% increase in operating income, even amid elevated mortality rates and hurricane impacts.
Furthermore, Fresenius raised its operating income guidance for the year to 16%-18% and announced the first positive same-market treatment growth in the U.S., along with an international increase of 3%.
Cost savings from the FME25 program exceeded the initial 2024 goal, reaching €173 million by the end of Q3. The company also revealed plans for the U.S. launch of its HDF-enabled 5008X machine by late 2025 and a focus on supply chain optimization. Despite the negative impact of virtual power purchase agreements (vPPAs) on earnings, Fresenius reiterated its commitment to achieving carbon neutrality by 2040.
While the company is reviewing underperforming clinics for potential closure, staffing levels have improved. Looking ahead, Fresenius confirmed its revenue growth outlook for 2024 and scheduled a Capital Markets Day for June 17, 2025, in London, where future strategies will be detailed. These recent developments underline Fresenius Medical Care's determination to navigate challenges and deliver on its growth targets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.